A downtrend has been apparent in Sera Prognostics, Inc. (SERA) lately with too much selling pressure. The stock has declined 43.9% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicato ...

SALT LAKE CITY, May 29, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that members of the Sera team will participate in the following upcoming investor conferences:William Blair 45th Annual Growth Stock ConferenceDate: June 3 – 5, 20251X1 Meetings OnlyDoug Fisher, M.D., Strategic Advisor to Sera and former Chief Business Offic ...

Summary of Sera Prognostics (SERA) 2025 Conference Call Company Overview - **Company**: Sera Prognostics (SERA) - **Industry**: Diagnostics, specifically focused on preterm birth prediction Key Points and Arguments Preterm Birth Prediction - Current methods for predicting preterm births are limited, primarily relying on previous preterm births and short cervix, which only applies to a small percentage of mothers [1][2] - Approximately 3.6 million mothers give birth annually, with a significant portion being first-time mothers who lack identifiable risk factors for preterm birth [1] Test Approval and Regulation - The preterm test is classified as a lab-developed test (LDT) and is overseen by CAP and CLIA, not the FDA [4] - There is no current risk to commercialization despite potential future FDA oversight of LDTs [6][7] Reimbursement Strategy - Sera Prognostics has partnered with national payer Elevance to facilitate reimbursement, which is expected to expedite coverage compared to typical timelines for diagnostic companies [9][10] - The company has a Medicare code for the test priced at $750, with expectations for both commercial and Medicaid plans to provide coverage [14][10] Market Opportunity - The total addressable market (TAM) for the test is estimated at approximately 3.2 million women annually, representing a multibillion-dollar opportunity [16] - The company plans to target specific states with high rates of preterm births to drive adoption [18] Economic Impact - The test has demonstrated significant cost savings, with estimates showing that screening three to four mothers can save one NICU day, which costs between $4,500 and $20,000 [34][35] - The overall economic burden of preterm births in the U.S. is over $25 billion, with childbirth-related costs representing 27% of all inpatient costs in Medicaid [36] Clinical Utility and Data Collection - The PRIME study showed that the test could keep one out of five babies out of the NICU, generating excitement in the clinical community [31][39] - Sera Prognostics is collecting extensive data on pregnancy-related proteins, with plans to develop additional women's health products [29][30] Sales and Marketing Strategy - The company is expanding its sales force and has appointed a new Chief Commercial Officer to enhance its market presence [22] - Initial efforts will focus on three to five states with high preterm birth rates, leveraging relationships with key opinion leaders and payers [18] Financial Position - Sera Prognostics has raised $57 million, bringing total funding to $215 million, providing a runway until the end of 2028 to reach profitability [23][24] - The annual cash burn rate is between $25 million and $30 million, allowing for strategic growth and marketing efforts [24] Future Catalysts - Upcoming publications detailing the test's efficacy and economic impact are anticipated, along with traction with Medicaid plans [41][42] - The company aims to provide revenue guidance for fiscal 2026 as it gains visibility on volume and market uptake [43] Additional Important Insights - The test's pricing strategy is designed to ensure broad adoption, especially in light of potential Medicaid budget cuts [38] - The clinical community is eager for innovations that can significantly impact preterm birth outcomes, highlighting the test's potential to transform care [39][40]

Sera Prognostics, Inc. (SERA) has been beaten down lately with too much selling pressure. While the stock has lost 30.5% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscil ...

"Lee is a highly accomplished leader with commercial expertise in fostering innovation, supporting continuous optimization and driving sales and offers a history of strong performance within the healthcare and diagnostics space," said Zhenya Lindgardt, President and CEO of Sera Prognostics. "With Sera now in the commercial phase following the strong results of our pivotal PRIME study, Lee will play a critical role in expanding adoption and sales of our PreTRM Test and we enthusiastically welcome Lee to our ...

This quarterly report represents an earnings surprise of 16.67%. A quarter ago, it was expected that this company would post a loss of $0.23 per share when it actually produced a loss of $0.25, delivering a surprise of -8.70%. Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.25 per share a year ago. These figures are adjusted for non-recurring items. There are no easy answers to this key questi ...

Sera Prognostics (SERA) Q1 2025 Earnings Call May 07, 2025 05:00 PM ET Company Participants Peter Denardo - PresidentZhenya Lindgardt - President & CEOAustin Aerts - Chief Financial Officer Conference Call Participants None - AnalystDaniel Brennan - Analyst Operator Good afternoon, and welcome to the SeraPrognostics Conference Call to Review First Quarter Fiscal Year twenty twenty five Results. At this time, all participants are in a listen only mode. We will be facilitating a question and answer session to ...

Sera Prognostics (SERA) Q1 2025 Earnings Call May 07, 2025 05:00 PM ET Speaker0 Good afternoon, and welcome to the SeraPrognostics Conference Call to Review First Quarter Fiscal Year twenty twenty five Results. At this time, all participants are in a listen only mode. We will be facilitating a question and answer session toward the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Peter DeNardo of Capcom Partners for a few introduc ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40606 SERA PROGNOSTICS, INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 26-1911522 | | --- | --- | | (State or other jur ...

Exhibit 99.1 "Following the results of our full PRIME pivotal study being publicized we are leveraging them by engaging with key plan providers in focused geographic regions hard hit by premature birth," said Zhenya Lindgardt, President and CEO of Sera Prognostics. "While it will take some time to evolve, we anticipate that Medicaid providers in those areas will see the positive impact PreTRM can make in healthcare cost savings and patient outcomes, furthering adoption of the test." First Quarter 2025 Finan ...